MK-6194

Phase 2Biologic

Merck & Co.

MK-6194 is one of 125 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

124

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Atopic DermatitisActive, not recruiting

Ulcerative ColitisActive, not recruiting

VitiligoActive, not recruiting

Non-Segmental VitiligoTerminated

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Atopic DermatitisPhase 1

Active, not recruiting

Ulcerative ColitisPhase 1

Active, not recruiting

VitiligoPhase 2

Active, not recruiting

Non-Segmental VitiligoPhase 2

Terminated

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 2

Bepreve

BBausch Health Americas, Inc.

Phase 3

1 3

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 4

GR1802

GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Phase 3

1 5

Pegcrisantaspase

Jazz Pharmaceuticals

Phase 3

1 6

EBGLYSS

Eli Lilly

Preclinical

23 7

MK-6194

Merck & Co.

Phase 2

1 8

Cibinqo

Pfizer

Preclinical

11 9

Product 0405

FFougera Pharmaceuticals Inc.

Phase 3

3 10

Prograf

VVeloxis Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult1 trial

MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06649877·16 enrolled

Systemic Lupus Erythematosus1 trial

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT06161116·149 enrolled

Atopic Dermatitis1 trial

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT05450198·72 enrolled

Ulcerative Colitis1 trial

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT04924114·57 enrolled

Single Dose1 trial

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06821334·37 enrolled

1 more indication

Non-segmental Vitiligo1 trial

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Non-Segmental Vitiligo

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT06113328·169 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for MK-6194. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK-6194 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK-6194. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

MK-6194

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult1 trial

Systemic Lupus Erythematosus1 trial

Atopic Dermatitis1 trial

Ulcerative Colitis1 trial

Single Dose1 trial

Non-segmental Vitiligo1 trial

References

Drug Info

Quick Facts

Related News